Company / Accounts Receivable
Jazz Pharmaceuticals Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$830.7M
FY2025
5-year range
$563.4M / $830.7M
FY2021-FY2025
Trend
+15.9%
vs FY2024
Sector context
#20 of 115
Health Care
What the data says
Jazz Pharmaceuticals's accounts receivable of $831M is higher than 83% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 8 consecutive years, from $224M in FY2017 to $831M in FY2025.
Based on SEC 10-K filings.
$831M in FY2025 with a 5-year CAGR of +15.9%. Top quartile in the Health Care sector.
Improved from $706M to $831M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +8.4%
- 5-Year CAGR
- +15.9%
- 10-Year CAGR
- -
Sector benchmark
-25.7% below sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's accounts receivable has grown for 8 consecutive years.
- 5-year CAGR of +15.9%, indicating consistent growth.
- In FY2025, accounts receivable increased 15.9% year-over-year.
- Ranks #20 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $830.7M | +15.9% |
| FY2024 | $716.8M | +1.6% |
| FY2023 | $705.8M | +8.3% |
| FY2022 | $651.5M | +15.6% |
| FY2021 | $563.4M | +42.1% |
| FY2020 | $396.5M | +11.4% |
| FY2019 | $356.0M | +34.9% |
| FY2018 | $263.8M | +17.7% |
| FY2017 | $224.1M | -4.3% |
| FY2016 | $234.2M | +11.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026